Abstract:Wei-guang Yang, &ast Ao Sun, &ast Rong Zhu, Nan Liu, Wei-jie He, Lin-lin Liu Department of Nephrology, The First Affiliated Hospital of China Medical University, Shen Yang, Liao Ning, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lin-lin Liu, Department of Nephrology, The First Affiliated Hospital of China Medical University, 155 Nan Jing North Street in He Ping District, Shen Yang, Liao Ning, People's Republic of China, Email Background: Artemisinin (ART) is a safe and effective antimalarial drug. In recent years, antimalarial drugs have demonstrated a good therapeutic efficacy in IgA nephropathy, suggesting that this may become a new treatment option. Purpose: We aimed to evaluate the effect and mechanism of artemisinin in IgA nephropathy. Methods: In this study, CMap database was used to predict the artemisinin therapeutic effect for IgA nephropathy. A network pharmacology approach was applied to explore the unknown mechanism of artemisinin in IgA nephropathy. We used molecular docking to predict the binding affinity of artemisinin with the targets. A mouse model of IgA nephropathy was established to investigate the therapeutic effect of artemisinin on IgA nephropathy. In vitro, the cell counting Kit-8 assay was used to evaluate the cytotoxicity of artemisinin. Flow cytometry and PCR assays were used to detect the effects of artemisinin on oxidative stress and fibrosis in lipopolysaccharide (LPS)-stimulated mesangial cells. Western blot and immunofluorescence were used to detect the expression of pathway proteins. Results: CMap analysis showed artemisinin may reverse the expression levels of differentially expressed genes in IgA nephropathy. Eighty-seven potential targets of artemisinin in the treatment of IgA nephropathy were screened. Among them, 15 hub targets were identified. Enrichment analysis and GSEA analysis indicated that response to reactive oxygen species is the core biological process. AKT1 and EGFR had the highest docking affinity with artemisinin. In vivo, artemisinin could improve renal injury and fibrosis in mice. In vitro, artemisinin attenuated LPS-induced oxidative stress and fibrosis promoted AKT phosphorylation and Nrf2 nuclear translocation. Conclusion: Artemisinin reduced the level of fibrosis and oxidative stress with IgA nephropathy through the AKT/Nrf2 pathway, which provided an alternative treatment for IgAN. Keywords: IgA nephropathy, artemisinin, network pharmacology, AKT, Nrf2 IgA nephropathy (IgAN) is a prevalent glomerular disease that has been on the rise in recent years. Patients with IgAN are mostly young people between the ages of 20–30. Among these patients, approximately 50% will progress to end-stage renal disease (ESRD) within 20 years. 1,2 Currently, corticosteroids, immunosuppressive drugs and natural products derived from traditional Chinese medicine (TCM) have been used to treat IgAN, which showed efficacy in some patients. 3–5 However, these regimens were challenged for the heterogeneity of patients' responses and side effects. Identification of new therapies and exploration of the mechanisms of the therapies is a priority for IgAN. A few previous studies showed that hydroxychloroquine (HCQ), an antimalarial drug, may reduce proteinuria in IgAN without evidence of adverse events. 6,7 The mechanism may be associated with regulating the differentiation of CD4+ T cell subsets and mediating exosomes release. 8,9 Artemisinin (ART), another antimalarial drug, was also proven to benefit some kidney diseases. 8–10 ART is a sesquiterpene lactone extracted from the traditional Chinese plant Artemisia annua, which contains the specific endoperoxide bridge structure. In addition to significant antimalarial effects, artemisinin and its derivatives have exhibited other pharmacological properties, such as antitumor, antiviral, antifibrotic, and anti-inflammatory effects. 11–13 However, the existing mechanisms cannot fully explain the molecular protective mechanism of HCQ and ART in glomerular injury in IgAN. Previous study of IgAN lacked research on medication treatment targets based on big data. Therefore, we used bioinformatics and experimental validation to predict the mechanism of the ART for IgAN treatment, which provides new insights into the pharmacological properties of artemisinin in the treatment of IgAN. The flow chart of the study is shown in Figure 1. Figure 1 Flowchart of the study. Abbreviations : ART, Artemisinin; IgAN, IgA nephropathy; HT, Hub targets; HBP, Hub biological process. Microarray datasets were downloaded from Gene Expression Omnibus (GEO, http://www.ncbi.n -Abstract Truncated-

Dihydroartemisinin Inhibits the Proliferation of IgAN Mesangial Cells Through the Mtor Signaling Pathway.

Triptolide protects podocytes via autophagy in immunoglobulin A nephropathy.

Dihydroartemisinin Ameliorates Inflammatory Disease by Its Reciprocal Effects on Th and Regulatory T Cell Function Via Modulating the Mammalian Target of Rapamycin Pathway

Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-κB signaling and NLRP3 inflammasome activation by exosomes in rats

Exploration of Artemisinin Against IgA Nephropathy via AKT/Nrf2 Pathway by Bioinformatics and Experimental Validation

Histone Deacetylase Inhibitors Attenuate P-aIgA1-induced Cell Proliferation and Extracellular Matrix Synthesis in Human Renal Mesangial Cells in Vitro

Dihydroartemisinin attenuates autoimmune thyroiditis by inhibiting the CXCR3/PI3K/AKT/NF-κB signaling pathway

Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+ T cells and modulating gut microbiota

Acei/Arb Therapy for Iga Nephropathy: A Meta Analysis of Randomised Controlled Trials

Sinomenine Hydrochloride Protects IgA Nephropathy Through Regulating Cell Growth and Apoptosis of T and B Lymphocytes

Liuwei Dihuang Pills Inhibit Podocyte Injury and Alleviate IgA Nephropathy by Directly Altering Mesangial Cell-Derived Exosome Function and Secretion

TPN10466 ameliorates Concanavalin A-induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway

Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Dihydroartemisinin suppresses renal fibrosis in mice by inhibiting DNA-methyltransferase 1 and increasing Klotho

Dihydroarteannuin Ameliorates Collagen-Induced Arthritis Via Inhibiting B Cell Activation by Activating the FcγRIIb/Lyn/SHP-1 Pathway

Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K

Tetrandrine inhibits the proliferation of mesangial cells induced by enzymatically deglycosylated human IgA1 via IgA receptor/MAPK/NF-κB signaling pathway

Dihydroartemisinin Regulated the MMP-Mediated Cellular Microenvironment to Alleviate Rheumatoid Arthritis

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma Through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

Anti-inflammatory effects of triptolide on IgA nephropathy in rats